Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.

dc.contributor.author

Ying, RS

dc.contributor.author

Le, T

dc.contributor.author

Cai, WP

dc.contributor.author

Li, YR

dc.contributor.author

Luo, CB

dc.contributor.author

Cao, Y

dc.contributor.author

Wen, CY

dc.contributor.author

Wang, SG

dc.contributor.author

Ou, X

dc.contributor.author

Chen, WS

dc.contributor.author

Chen, SZ

dc.contributor.author

Guo, PL

dc.contributor.author

Chen, M

dc.contributor.author

Guo, Y

dc.contributor.author

Tang, XP

dc.contributor.author

Li, LH

dc.date.accessioned

2021-08-18T18:13:01Z

dc.date.available

2021-08-18T18:13:01Z

dc.date.issued

2020-12

dc.date.updated

2021-08-18T18:13:01Z

dc.description.abstract

Objectives

Talaromycosis is an invasive mycosis endemic to Southeast Asia. This study aimed to investigate the epidemiology, clinical features and prognostic factors of HIV-associated talaromycosis in Guangdong, China.

Methods

We retrospectively evaluated HIV patients hospitalized with histopathology- or culture-confirmed talaromycosis between 2011 and 2017. Factors associated with poor prognosis were identified using logistic regression.

Results

Overall, 1079 patients with HIV-associated talaromycosis were evaluated. Both the number and prevalence of talaromycosis among HIV admissions increased from 125 and 15.7% in 2011 to 253 and 18.8% in 2017, respectively, reflecting the increase in HIV admissions. Annual admissions peaked during the rainy season between March and August. Common clinical manifestations included fever (85.6%), peripheral lymphadenopathy (72.3%), respiratory symptoms (60.8%), weight loss (49.8%), skin lesions (44.5%) and gastrointestinal symptoms (44.3%). Common laboratory abnormalities were hypoalbuminaemia (98.6%), anaemia (95.6%), elevated aspartate aminotransferase level (AST) (76.9%), elevated alkaline phosphatase level (55.8%) and thrombocytopenia (53.7%). The median CD4 count was 9 cells/μL. Talaromyces marneffei was isolated from blood and bone marrow cultures of 66.6% and 74.5% of patients, respectively. The rate increased to 86.6% when both cultures were performed concurrently. At discharge, 14% of patients showed worsening conditions or died. Leucocytosis, thrombocytopenia, elevated AST, total bilirubin, creatinine and azole monotherapy independently predicted poor prognosis.

Conclusions

The incidence of HIV-associated talaromycosis has increased in Guangdong with the high HIV burden in China. Skin lesions were seen in less than half of patients. Induction therapy with azole alone is associated with higher mortality. Findings from this study should help to improve treatment of the disease.
dc.identifier.issn

1464-2662

dc.identifier.issn

1468-1293

dc.identifier.uri

https://hdl.handle.net/10161/23601

dc.language

eng

dc.publisher

Wiley

dc.relation.ispartof

HIV medicine

dc.relation.isversionof

10.1111/hiv.13024

dc.subject

China

dc.subject

HIV

dc.subject

Talaromyces marneffei

dc.subject

penicilliosis

dc.subject

talaromycosis

dc.title

Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.

dc.type

Journal article

duke.contributor.orcid

Le, T|0000-0002-3393-6580

pubs.begin-page

729

pubs.end-page

738

pubs.issue

11

pubs.organisational-group

School of Medicine

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

Duke Global Health Institute

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Duke

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

21

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Clinical epidemiology and outcome of talaromycosis in Guangdong 2011-2017_HIV Medicine 2020.pdf
Size:
245.35 KB
Format:
Adobe Portable Document Format
Description:
Published version